Clinical trials: Antipsychotic
Post-Traumatic Stress Disorder
Risperidone Augmentation for PTSD
The purpose of this study is to (1) compare the response of civilians with Posttraumatic Stress Disorder(PTSD) currently receiving sertraline without an optimal response to risperidone augmentation vs.
- Trial name
- NCT00215241
- Testing
- sertraline and risperidone
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Duke University
Bipolar Disorder
Subjective Well Being of Patients Receiving Atypical Antipsychotics as Monotherapy or Cotherapy With Mood Stabilizers
Cross - Sectional study requiring one visit at the investigators office for the data collection. Target Group: Patients that suffer from Bipolar Disorder Type 1.
- Trial name
- DIDAXI (NCT00691353)
- Where
- 20 sites in Greece
- Volunteers
- 540 people
- Sponsor
- AstraZeneca
Psychotic Disorders
Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting
Despite different pharmacological properties, the scientific evidence is inconclusive regarding which of the first-line second generation antipsychotics (SGAs) should be preferred for the individual patient suffering from…
- Trial name
- BPP (NCT00932529)
- Testing
- Olanzapine, Quetiapine, Risperidone
- Where
- Norway
- Volunteers
- 226 people
- Sponsor
- University of Bergen
Treatment-resistant Schizophrenia
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
This is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety, and tolerability of a dose of evenamide of 15 mg bid, compared to placebo, as add-on treatment in…
- Trial name
- ENIGMA-TRS 2 (NCT07184619)
- Testing
- Evenamide 15 mg bid
- Where
- 19 sites in United States, Argentina and 2 more
- Volunteers
- 400 people
- Sponsor
- Newron Pharmaceuticals SPA
Schizophrenia
Novel Candidate Genes for Treatment Response to Antipsychotics in Schizophrenia
Schizophrenia is a severe and chronic mental disorder. The lifetime risk of schizophrenia is around 1%. Its course is chronic and frequently disabling. The keystone of schizophrenia treatment is antipsychotic medications.
- Trial name
- GEXANT (NCT02205437)
- Where
- Spain
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Psychotic Disorders, Schizophrenia Spectrum Disorders (SSD)
Multimodal Physical Exercise Program (Physical Exercise for Psychosis) for People With Psychosis Treated With Long-Acting Injectable Antipsychotics
People with psychotic disorders, such as schizophrenia, often experience significant difficulties in daily functioning, physical health, and quality of life.
- Conditions
- Psychotic Disorders, Schizophrenia Spectrum Disorders (SSD), Severe Mental Illness
- Trial name
- PEP (NCT07360665)
- Testing
- Physical Exercise
- Where
- Portugal
- Volunteers
- 44 people
- Sponsor
- University of Trás-os-Montes and Alto Douro
Schizophrenia, Schizoaffective Disorder
Anticholinergic Burden in Schizophrenia
Anticholinergic antiparkinsonian agents often cause side-effects including cognitive impairment, dry mouth, and constipation while they diminish antipsychotic-induced parkinsonian symptoms.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Delusional Disorder
- Trial name
- NCT00715377
- Testing
- Benztropine
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Centre for Addiction and Mental Health
Bipolar Disorders, Manic Episode
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder
The purpose of the study is to assess the effectiveness and safety of risperidone (an antipsychotic medication) versus placebo during 3 weeks of treatment of mania in patients with Bipolar I Disorder who are suffering a manic…
- Trial name
- NCT00257075
- Testing
- Risperidone, oral tablets
- Volunteers
- 267 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia
This is an observational, non-interventional study that will include two cohorts of patients with schizophrenia who initiated maintenance treatment during a schizophrenia-related hospitalisation or during the immediate three…
- Trial name
- NCT03130465
- Where
- 67 sites in France, Germany and 2 more
- Volunteers
- 636 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Schizophrenia
Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia
This study will examine the effects of ondansetron on auditory nerve activity in people with schizophrenia who are being treated with new antipsychotics.
- Trial name
- NCT00149734
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Colorado, Denver
Psychotic Disorders, Gastroesophageal Reflux
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
The purpose of this 9-day study is to determine if: 1. Pantoprazole modifies the steady-state plasma concentrations of orally administered psychotropic medications including valproic acid, lithium, and second-generation…
- Trial name
- PK-PPI (NCT02213887)
- Testing
- Pantoprazole
- Where
- Canada
- Sponsor
- University of British Columbia
Schizophrenia
The Danish Region Midt Schizophrenia Cohort
The objective of this study is to recruit patients at the first diagnosis with a schizophrenia spectrum disorder (SSD) and ultra-high risk patients (UHR), defined as patients with drug abuse and psychotic symptoms indicating a…
- Trial name
- RMS (NCT06431009)
- Testing
- Treatment-as-usual
- Where
- 5 sites in Denmark
- Volunteers
- 350 people
- Sponsor
- University of Aarhus
Schizophrenia, Tranquilizing Agents
A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)
This study is a non-interventional web based registry designed to assess demographic, treatment and outcomes data in patients receiving treatment with long-acting injectable risperidone.
- Conditions
- Schizophrenia, Tranquilizing Agents, Mental Disorders, Therapeutic Uses
- Trial name
- NCT00294008
- Testing
- Risperdal Consta
- Volunteers
- 230 people
- Sponsor
- Janssen Korea, Ltd., Korea
Psychotic Disorders
Effect of Antipsychotics on Appetite Regulation
The purpose of this study is to evaluate changes in appetite-regulating hormones, body composition (weight, body fat%), and hunger ratings in persons early in treatment with one of four atypical antipsychotic medications…
- Trial name
- ADAPT (NCT00903916)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia
Appetite Increase in Schizophrenia Patients Treated With Atypical Antipsychotics
The purpose of this study is to understand, with the use of functional magnetic resonance imaging, the neural correlates involved in appetite control and the mechanism of weight gain in patients with schizophrenia treated with…
- Trial name
- NCT00290121
- Testing
- Olanzapine
- Where
- Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Université de Montréal
Schizophrenia, Schizoaffective Disorder
Allopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as add-on Antipsychotics in Patients With Schizophrenia
The objective of the study is to evaluate the efficacy of allopurinol, compared to placebo, as add-on to anti-psychotics in the treatment of patients with schizophrenia.
- Trial name
- NCT00864825
- Testing
- Allopurinol
- Where
- 33 sites in Israel, Romania
- Volunteers
- 248 people
- Sponsor
- Sheba Medical Center
Schizophrenia
Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis
A controlled, randomized study on the treatment of schizophrenic psychosis with cannabidiol, a phytocannabinoid is performed. This approach is based upon recent findings indicating that the human endogenous cannabinoid system is…
- Trial name
- CBD-CT1 (NCT00628290)
- Testing
- Cannabidiol, Amisulpride
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- University of Cologne
Psychosis, Agitation
Ziprasidone vs Standard Therapy for Agitated Patients in the ED
The primary objective is to determine if ziprasidone is superior to standard therapies in the emergency department treatment of the acutely agitated patient.
- Conditions
- Psychosis, Agitation, Delirium
- Trial name
- NCT00786318
- Testing
- ziprasidone, Standard therapy
- Where
- United States
- Sponsor
- George Washington University
Schizophrenia
A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.
The purpose of this study is to evaluate the efficacy of paliperidone palmitate compared with placebo in the prevention of recurrence of the symptoms of schizophrenia and to assess the safety and tolerability of paliperidone…
- Trial name
- NCT00111189
- Testing
- Paliperidone Palmitate
- Where
- 55 sites in United States, Costa Rica and 7 more
- Volunteers
- 414 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Comparing the Effects of Sertindole and Olanzapine on Cognition (SEROLA)
Cognition is one of the core symptoms of schizophrenia. This study is a head-to-head trial between olanzapine and sertindole with cognition as primary outcome.
- Trial name
- SEROLA (NCT00885690)
- Testing
- Sertindole, Olanzapine
- Where
- 2 sites in Denmark, Sweden
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Aarhus